Hematologic Oncology

David M. Swoboda, MD, discusses the roles of available TKIs for the treatment of patients with chronic myeloid leukemia.

Vivek Patel, MD, discusses the safety of bispecific antibodies and the choice between these agents and CAR T-cell therapy for follicular lymphoma.

Rituximab monotherapy delayed the time to next treatment vs watchful waiting in advanced stage, asymptomatic, low tumor burden follicular lymphoma.

Updated NCCN Guidelines recommend pemivibart in immunocompromised patients with B-cell lymphomas who are at higher risk of contracting COVID-19.

Vivek Patel, MD, discusses the evolving roles of chemoimmunotherapy and bispecific antibodies in the first-line follicular lymphoma setting.

FDA’s ODAC voted on therapeutic approaches in lymphoma, bladder, prostate, and myeloma, and more from OncLive this week.

Vivek G. Patel, MD, discusses the potential advantages of subcutaneous bispecific antibodies that are being evaluated in frontline follicular lymphoma.

Andrew Ip, MD, discusses how the limitations of real-world studies reveal gaps in LBCL research that future CAR T-cell therapy clinical trials may address.

The EMA’s CHMP has recommended the approval of obecabtagene autoleucel for adult patients with relapsed/refractory B-ALL.

Two-year follow-up data continued to show an overall survival benefit with glofitamab plus chemotherapy in relapsed/refractory DLBCL.

Multiple experts on artificial intelligence in cancer care discuss its ever-expanding role in several areas of oncology.

Lia Gore, MD, and Sarah K. Tasian, MD, discuss ongoing research in pediatric acute leukemia.

Lia Gore, MD, and Sarah K. Tasian, MD, discuss key factors for the management of pediatric acute leukemia.

Lia Gore, MD, and Sarah K. Tasian, MD, discuss treatment expectations with revumenib in pediatric relapsed/refractory acute leukemia.

Lia Gore, MD, and Sarah K. Tasian, MD, discuss the use of 25-mg tablets of revumenib in pediatric KMT2A-translocated relapsed/refractory acute leukemia.

Lia Gore, MD, and Sarah K. Tasian, MD, discuss the optimal timing of testing for KMT2A rearrangements in pediatric acute leukemia.

Lia Gore, MD, and Sarah K. Tasian, MD, on the significance of the FDA approval of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia.

Lia Gore, MD, and Sarah K. Tasian, MD, discuss current treatment trends in pediatric relapsed/refractory acute leukemia.

Pola-R-CHP demonstrated clinically meaningful PFS and safety in older patients with previously untreated diffuse large B-cell lymphoma.

Tafasitamab plus lenalidomide has received NMPA approval for patients with relapsed/refractory DLBCL who are ineligible for ASCT.

Lorenzo Falchi, MD, discusses the safety and pharmacodynamics of fixed-duration epcoritamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma

Lymphodepletion was associated with enhanced MAR T-cell response and antitumor activity with MT-601 in patients with relapsed/refractory lymphoma.

The FDA’s ODAC voted against the applicability of STARGLO trial results to U.S. patients with relapsed/refractory DLBCL.

Oncology experts detail their most highly-anticipated hematology abstracts and data to watch at the upcoming 2025 ASCO Annual Meeting.

Olalekan O. Oluwole, MD, MPH, discusses how AE assessment could guide post-infusion monitoring periods and outpatient axi-cel administration in LBCL.